Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Astra Merck

  • News

Executive Summary

Astra Merck: Nancy Wysenski to VP-sales and Barry Greene to VP-marketing and customer services, filling roles vacated by VP-Sales and Marketing Matthew Emmens. Emmens was named acting CEO Jan. 17, replacing Wayne Yetter, who departed to lead Novartis' U.S. pharmaceuticals business ("The Pink Sheet" Feb. 3, T&G-1). Wysenski was executive director of field sales at Astra Merck; Greene had worked on process design for Astra Merck's sales and marketing organization as an associate partner with Andersen Consulting. Astra Merck also announces the promotions of VP-Drug Development Irwin Scher to chief medical officer and senior VP-drug development; VP-Portfolio Management Dave Brennan to senior VP-business operations; and Rob Cohen, VP-information technology, to chief information officer...

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS029715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By